Top Markets
#1 PulseChain PulseChain +48.38%
#2 Ergo Ergo +22.78%
#3 Not in Employment, Education, or Training Not in Employment, Education, or Training +17.06%
#4 RedStone RedStone +15.48%
#5 SkyAI SkyAI +11.00%
#6 Lighter Lighter +9.58%
#7 MarsCoin MarsCoin +9.07%
#8 OPENLOOT OPENLOOT +8.87%
#9 Monad Monad +8.43%
#10 Lorenzo Wrapped Bitcoin Lorenzo Wrapped Bitcoin +7.93%
Coin of the day
PulseChain PulseChain
Настройки
Язык
Pусский
Валюта
USD
Тема
Marinus Pharmaceuticals, Inc. Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc.

MRNS
Ранг среди акций #28050
Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated... Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated to the development and commercialization of therapeutic solutions for individuals suffering from rare genetic epilepsies and other seizure-related conditions. The company's primary commercialized product is ZTALMY, an oral suspension specifically designed to manage seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD). This medication is prescribed for both adult and pediatric patient populations, suitable for use in acute and chronic care settings, and can be administered either in-patient or by the patient themselves. ZTALMY exerts its effect by targeting synaptic and extrasynaptic GABAA receptors, a mechanism that also suggests potential anticonvulsant, antidepressant, and anxiolytic benefits. Beyond ZTALMY, Marinus is actively progressing ganaxolone through development, an investigational therapy aimed at various genetic epileptic conditions such as PCDH19-related epilepsy, tuberous sclerosis complex, and Lennox-Gastaut Syndrome, with additional exploration for depressive disorders. The company maintains strategic alliances, including licensing agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc., as well as a collaborative partnership with Orion Corporation. Marinus Pharmaceuticals was established in 2003 and operates from its corporate headquarters in Radnor, Pennsylvania.
Цена акции
$0.55
Последняя синхронизация: 2025-02-11
Рыночная капитализация
$28.90M
Изменение (1 день)
0.00%
Изменение (1 год)
0.00%
Страна
US
Торговля Marinus Pharmaceuticals, Inc. (MRNS)

Категория

Healthcare
Операционная маржа для Marinus Pharmaceuticals, Inc. (MRNS)
Операционная маржа на August 2026 TTM: -424.30%
Согласно последним финансовым отчетам и цене акций Marinus Pharmaceuticals, Inc., текущая операционная маржа (TTM) составляет -424.30%. В конце 2022 она составила -442.69%.
История операционной маржи Marinus Pharmaceuticals, Inc. с 2012 по 2026
Операционная маржа на конец каждого года
Год Операционная маржа Изменить
2026 (TTM) -424.30% 0.00%
2023 -424.30% -4.15%
2022 -442.69% -29.92%
2021 -631.68% -84.03%
2020 -3,954.42% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
2016 0.00% 0.00%
2015 0.00% 0.00%
2014 0.00% 0.00%
2013 0.00% -100.00%
2012 -1,430.66% 0.00%
Операционная маржа для аналогичных компаний или конкурентов
Компания Операционная маржа Разница в операционной марже Страна
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -100.09%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -99.65%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -100.07%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -100.06%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Что такое операционная маржа компании?
Операционная маржа — это ключевой показатель прибыльности компании. Более высокая операционная маржа обычно означает, что компания может продавать свои товары или услуги значительно дороже их себестоимости. Она рассчитывается путем деления прибыли компании на её выручку.